131 related articles for article (PubMed ID: 20349427)
1. New pathways to renal damage: role of ADMA in retarding renal disease progression.
Ueda S; Yamagishi S; Okuda S
J Nephrol; 2010; 23(4):377-86. PubMed ID: 20349427
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
Ueda S; Yamagishi S; Kaida Y; Okuda S
Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
[TBL] [Abstract][Full Text] [Related]
4. Role of asymmetric dimethylarginine in cardiorenal syndrome.
Ueda S; Yamagishi S; Yokoro M; Okuda S
Curr Pharm Des; 2014; 20(14):2448-55. PubMed ID: 23844812
[TBL] [Abstract][Full Text] [Related]
5. [Methylarginies-induced endothelial dysfunction in chronic kidney disease].
Kimura K
Yakugaku Zasshi; 2012; 132(4):443-8. PubMed ID: 22465920
[TBL] [Abstract][Full Text] [Related]
6. Role of asymmetrical dimethylarginine in the progression of renal disease.
Raptis V; Kapoulas S; Grekas D
Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674
[TBL] [Abstract][Full Text] [Related]
7. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Matsumoto Y; Ueda S; Yamagishi S; Matsuguma K; Shibata R; Fukami K; Matsuoka H; Imaizumi T; Okuda S
J Am Soc Nephrol; 2007 May; 18(5):1525-33. PubMed ID: 17409314
[TBL] [Abstract][Full Text] [Related]
8. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease.
Fliser D
J Nephrol; 2010; 23(4):369-76. PubMed ID: 20349425
[TBL] [Abstract][Full Text] [Related]
9. The endothelium as a target in renal diseases.
Zoccali C
J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
McCarty MF
Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
[TBL] [Abstract][Full Text] [Related]
11. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
Matsuguma K; Ueda S; Yamagishi S; Matsumoto Y; Kaneyuki U; Shibata R; Fujimura T; Matsuoka H; Kimoto M; Kato S; Imaizumi T; Okuda S
J Am Soc Nephrol; 2006 Aug; 17(8):2176-83. PubMed ID: 16807406
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
Mihout F; Shweke N; Bigé N; Jouanneau C; Dussaule JC; Ronco P; Chatziantoniou C; Boffa JJ
J Pathol; 2011 Jan; 223(1):37-45. PubMed ID: 20845411
[TBL] [Abstract][Full Text] [Related]
14. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
Gilinskiĭ MA
Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
[TBL] [Abstract][Full Text] [Related]
15. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
Kielstein JT; Zoccali C
Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide synthase derangements and hypertension in kidney disease.
Baylis C
Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):1-6. PubMed ID: 22048724
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Kielstein JT; Zoccali C
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):609-15. PubMed ID: 18941355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
